Voss Capital LP Invests $2.40 Million in Kura Oncology, Inc. (NASDAQ:KURA)

Voss Capital LP acquired a new position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 275,000 shares of the company's stock, valued at approximately $2,395,000. Voss Capital LP owned approximately 0.35% of Kura Oncology as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of KURA. Harbor Advisors LLC bought a new position in shares of Kura Oncology during the 4th quarter worth $87,000. E Fund Management Co. Ltd. bought a new position in Kura Oncology during the 4th quarter worth about $90,000. Optimize Financial Inc bought a new stake in shares of Kura Oncology in the 4th quarter valued at about $100,000. Corient Private Wealth LLC purchased a new stake in shares of Kura Oncology in the 4th quarter worth approximately $109,000. Finally, Teacher Retirement System of Texas boosted its stake in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after purchasing an additional 2,285 shares in the last quarter.

Insider Transactions at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company's stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last 90 days. 6.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. StockNews.com raised Kura Oncology from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Kura Oncology presently has an average rating of "Moderate Buy" and an average target price of $25.50.

Kura Oncology Stock Performance

Shares of KURA remained flat at $6.43 during mid-day trading on Friday. 984,566 shares of the company traded hands, compared to its average volume of 1,147,182. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $23.48. The stock has a market cap of $519.40 million, a PE ratio of -2.72 and a beta of 0.83. The firm's fifty day simple moving average is $6.88 and its 200 day simple moving average is $10.05.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. Research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.